ReviewESMO open2018

Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis.

Marina Chiara Garassino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.